Logo image of MASI

MASIMO CORP (MASI) Stock Fundamental Analysis

NASDAQ:MASI - Nasdaq - US5747951003 - Common Stock - Currency: USD

162.68  -0.31 (-0.19%)

Fundamental Rating

4

MASI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. MASI has an average financial health and profitability rating. MASI has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year MASI was profitable.
In the past year MASI had a positive cash flow from operations.
MASI had positive earnings in 4 of the past 5 years.
Each year in the past 5 years MASI had a positive operating cash flow.
MASI Yearly Net Income VS EBIT VS OCF VS FCFMASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

MASI has a Return On Assets (-21.56%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -52.25%, MASI is in line with its industry, outperforming 47.06% of the companies in the same industry.
MASI has a Return On Invested Capital of 3.74%. This is in the better half of the industry: MASI outperforms 73.80% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MASI is below the industry average of 7.89%.
Industry RankSector Rank
ROA -21.56%
ROE -52.25%
ROIC 3.74%
ROA(3y)-1.49%
ROA(5y)4.35%
ROE(3y)-4.1%
ROE(5y)3.92%
ROIC(3y)4.58%
ROIC(5y)8.17%
MASI Yearly ROA, ROE, ROICMASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

MASI has a better Operating Margin (4.19%) than 68.98% of its industry peers.
MASI's Operating Margin has declined in the last couple of years.
MASI has a Gross Margin (50.50%) which is comparable to the rest of the industry.
MASI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 4.19%
PM (TTM) N/A
GM 50.5%
OM growth 3Y-55.93%
OM growth 5Y-39.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.74%
GM growth 5Y-6.5%
MASI Yearly Profit, Operating, Gross MarginsMASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

MASI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
MASI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MASI remains at a similar level compared to 5 years ago.
MASI has a better debt/assets ratio than last year.
MASI Yearly Shares OutstandingMASI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
MASI Yearly Total Debt VS Total AssetsMASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

MASI has an Altman-Z score of 6.06. This indicates that MASI is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.06, MASI belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
The Debt to FCF ratio of MASI is 4.48, which is a neutral value as it means it would take MASI, 4.48 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MASI (4.48) is better than 83.42% of its industry peers.
MASI has a Debt/Equity ratio of 0.67. This is a neutral value indicating MASI is somewhat dependend on debt financing.
The Debt to Equity ratio of MASI (0.67) is worse than 68.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF 4.48
Altman-Z 6.06
ROIC/WACC0.43
WACC8.61%
MASI Yearly LT Debt VS Equity VS FCFMASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.17 indicates that MASI has no problem at all paying its short term obligations.
The Current ratio of MASI (2.17) is worse than 60.96% of its industry peers.
MASI has a Quick Ratio of 1.62. This is a normal value and indicates that MASI is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.62, MASI perfoms like the industry average, outperforming 44.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.62
MASI Yearly Current Assets VS Current LiabilitesMASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.12% over the past year.
Measured over the past 5 years, MASI shows a small growth in Earnings Per Share. The EPS has been growing by 5.86% on average per year.
Looking at the last year, MASI shows a decrease in Revenue. The Revenue has decreased by -0.12% in the last year.
MASI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.43% yearly.
EPS 1Y (TTM)58.12%
EPS 3Y2.37%
EPS 5Y5.86%
EPS Q2Q%76.62%
Revenue 1Y (TTM)-0.12%
Revenue growth 3Y19.12%
Revenue growth 5Y17.43%
Sales Q2Q%-24.51%

3.2 Future

MASI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.87% yearly.
Based on estimates for the next years, MASI will show a decrease in Revenue. The Revenue will decrease by -0.41% on average per year.
EPS Next Y18.58%
EPS Next 2Y13.54%
EPS Next 3Y14.5%
EPS Next 5Y10.87%
Revenue Next Year-27.16%
Revenue Next 2Y-11.41%
Revenue Next 3Y-5.32%
Revenue Next 5Y-0.41%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MASI Yearly Revenue VS EstimatesMASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
MASI Yearly EPS VS EstimatesMASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

MASI is valuated quite expensively with a Price/Earnings ratio of 33.40.
Compared to the rest of the industry, the Price/Earnings ratio of MASI indicates a somewhat cheap valuation: MASI is cheaper than 72.19% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. MASI is valued slightly more expensive when compared to this.
Based on the Price/Forward Earnings ratio of 29.48, the valuation of MASI can be described as expensive.
Based on the Price/Forward Earnings ratio, MASI is valued a bit cheaper than 71.66% of the companies in the same industry.
MASI's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 35.19.
Industry RankSector Rank
PE 33.4
Fwd PE 29.48
MASI Price Earnings VS Forward Price EarningsMASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MASI indicates a somewhat cheap valuation: MASI is cheaper than 64.71% of the companies listed in the same industry.
72.19% of the companies in the same industry are more expensive than MASI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 60.71
EV/EBITDA 55.04
MASI Per share dataMASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

MASI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
MASI's earnings are expected to grow with 14.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.8
PEG (5Y)5.7
EPS Next 2Y13.54%
EPS Next 3Y14.5%

More info and screens

0

5. Dividend

5.1 Amount

MASI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MASIMO CORP

NASDAQ:MASI (7/14/2025, 9:36:17 AM)

162.68

-0.31 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners101.51%
Inst Owner Change0.14%
Ins Owners0.17%
Ins Owner Change3.35%
Market Cap8.82B
Analysts82.67
Price Target185.71 (14.16%)
Short Float %6.57%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.57%
Min EPS beat(2)10.25%
Max EPS beat(2)14.9%
EPS beat(4)4
Avg EPS beat(4)12.57%
Min EPS beat(4)10.25%
Max EPS beat(4)14.9%
EPS beat(8)8
Avg EPS beat(8)11.42%
EPS beat(12)12
Avg EPS beat(12)10.04%
EPS beat(16)16
Avg EPS beat(16)8.47%
Revenue beat(2)0
Avg Revenue beat(2)-0.68%
Min Revenue beat(2)-0.77%
Max Revenue beat(2)-0.59%
Revenue beat(4)0
Avg Revenue beat(4)-1.09%
Min Revenue beat(4)-1.58%
Max Revenue beat(4)-0.59%
Revenue beat(8)0
Avg Revenue beat(8)-2.4%
Revenue beat(12)3
Avg Revenue beat(12)-1.34%
Revenue beat(16)6
Avg Revenue beat(16)-0.91%
PT rev (1m)0%
PT rev (3m)-6.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.99%
EPS NY rev (1m)-3.42%
EPS NY rev (3m)-5.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE 33.4
Fwd PE 29.48
P/S 4.47
P/FCF 60.71
P/OCF 48.54
P/B 9.32
P/tB 11.2
EV/EBITDA 55.04
EPS(TTM)4.87
EY2.99%
EPS(NY)5.52
Fwd EY3.39%
FCF(TTM)2.68
FCFY1.65%
OCF(TTM)3.35
OCFY2.06%
SpS36.4
BVpS17.45
TBVpS14.53
PEG (NY)1.8
PEG (5Y)5.7
Profitability
Industry RankSector Rank
ROA -21.56%
ROE -52.25%
ROCE 4.73%
ROIC 3.74%
ROICexc 4.04%
ROICexgc 4.48%
OM 4.19%
PM (TTM) N/A
GM 50.5%
FCFM 7.36%
ROA(3y)-1.49%
ROA(5y)4.35%
ROE(3y)-4.1%
ROE(5y)3.92%
ROIC(3y)4.58%
ROIC(5y)8.17%
ROICexc(3y)4.95%
ROICexc(5y)12.77%
ROICexgc(3y)9.27%
ROICexgc(5y)17.89%
ROCE(3y)5.8%
ROCE(5y)10.34%
ROICexcg growth 3Y-55.81%
ROICexcg growth 5Y-40.49%
ROICexc growth 3Y-58.97%
ROICexc growth 5Y-44.46%
OM growth 3Y-55.93%
OM growth 5Y-39.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.74%
GM growth 5Y-6.5%
F-Score5
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF 4.48
Debt/EBITDA 3.74
Cap/Depr 41.7%
Cap/Sales 1.84%
Interest Coverage 2.13
Cash Conversion 106.88%
Profit Quality N/A
Current Ratio 2.17
Quick Ratio 1.62
Altman-Z 6.06
F-Score5
WACC8.61%
ROIC/WACC0.43
Cap/Depr(3y)60.07%
Cap/Depr(5y)110.25%
Cap/Sales(3y)3.16%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.12%
EPS 3Y2.37%
EPS 5Y5.86%
EPS Q2Q%76.62%
EPS Next Y18.58%
EPS Next 2Y13.54%
EPS Next 3Y14.5%
EPS Next 5Y10.87%
Revenue 1Y (TTM)-0.12%
Revenue growth 3Y19.12%
Revenue growth 5Y17.43%
Sales Q2Q%-24.51%
Revenue Next Year-27.16%
Revenue Next 2Y-11.41%
Revenue Next 3Y-5.32%
Revenue Next 5Y-0.41%
EBIT growth 1Y-49.63%
EBIT growth 3Y-47.5%
EBIT growth 5Y-29%
EBIT Next Year47.29%
EBIT Next 3Y17.22%
EBIT Next 5Y14.45%
FCF growth 1Y422.89%
FCF growth 3Y-14.18%
FCF growth 5Y-0.52%
OCF growth 1Y2653.03%
OCF growth 3Y-9.48%
OCF growth 5Y-2.39%